Lung Cancer Surgery Market - Emerging Economies to Bring Major Growth Prospects

This study involved four major activities in estimating the current size of the lung cancer surgery market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.

Overview of This Study:

This study involved four major activities in estimating the current size of the lung cancer surgery market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments market size.

Major Growth Driving Factors:

Market growth is largely driven by factors such as the technological advancements in lung cancer treatment, increasing incidence and prevalence of lung cancer, growing trend of smoking tobacco, rising geriatric population, increasing emphasis on early diagnosis treatment of cancers, and availability of reimbursement. However, the high cost of lung cancer diagnosis surgery is expected to restrain the growth of this market during the forecast period.

Market Size Estimation:

Both top-down and bottom-up approaches were used to estimate and validate the lung cancer surgery market total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

# The key players in the industry have been identified through extensive secondary research
# The revenues generated by leading players operating in the lung cancer surgery market have been determined through primary and secondary research
# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222

Expected Revenue Growth:

The global lung cancer surgery market is projected to reach USD 6.7 billion by 2026 from USD 5.4 billion in 2020, at a CAGR of 3.8% during the forecast period.

Data Triangulation:

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Recent Developments:

# In May 2021, Olympus Corporation (Japan) launched BF-UC190F endobronchial ultrasound (EBUS) bronchoscope.

# In February 2020, Intuitive Surgical Inc. (US) acquired Orpheus Medical (US).

# In October 2019, KLS Martin Group (Germany) opened a new training center at its site in Jacksonville, Florida, US.

Geographical Growth Dynamics:

North America is the largest regional market for lung cancer surgery market

In 2020, North America accounted for the largest market share. The large share of North America can be attributed to rising technological advancements in lung cancer treatment, increasing incidence and prevalence of lung cancer, rising trend of smoking tobacco, increasing emphasis on early diagnosis treatment of cancers, and the availability of reimbursement.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=222

COVID-19 Impact on Global Lung cancer surgery market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a few weeks. The number of cancer screening and diagnostic procedures declined precipitously, with countries worldwide affected by the pandemic.

An initial analysis of the US market shows that newly diagnosed metastatic non-small-cell lung cancer patient volumes have declined just over 30% from February 2020 to March 2020—this represents a major decline in just one month. This also impacted rate of surgeries that benefit certain patients.


Makarand Vaidya

246 Blog posts

Comments